CN120346304A - 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 - Google Patents
用于治疗自身免疫性疾病的白细胞介素-2突变蛋白Info
- Publication number
- CN120346304A CN120346304A CN202510423645.4A CN202510423645A CN120346304A CN 120346304 A CN120346304 A CN 120346304A CN 202510423645 A CN202510423645 A CN 202510423645A CN 120346304 A CN120346304 A CN 120346304A
- Authority
- CN
- China
- Prior art keywords
- fold
- amino acid
- seq
- agent
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309293P | 2022-02-11 | 2022-02-11 | |
| US63/309,293 | 2022-02-11 | ||
| PCT/US2023/062395 WO2023154870A1 (en) | 2022-02-11 | 2023-02-10 | Interleukin-2 muteins for the treatment of autoimmune diseases |
| CN202380019852.2A CN119013034A (zh) | 2022-02-11 | 2023-02-10 | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380019852.2A Division CN119013034A (zh) | 2022-02-11 | 2023-02-10 | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120346304A true CN120346304A (zh) | 2025-07-22 |
Family
ID=85476118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510423645.4A Pending CN120346304A (zh) | 2022-02-11 | 2023-02-10 | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 |
| CN202380019852.2A Pending CN119013034A (zh) | 2022-02-11 | 2023-02-10 | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380019852.2A Pending CN119013034A (zh) | 2022-02-11 | 2023-02-10 | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230390360A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475875A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506173A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240148001A (cg-RX-API-DMAC7.html) |
| CN (2) | CN120346304A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023219773A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243493A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009868A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400218A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154870A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| TW202333772A (zh) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | 使用介白素-2藥劑之方法 |
| WO2026154422A1 (en) * | 2025-01-17 | 2026-07-23 | Otsuka Pharmaceutical Company, Ltd. | Il-2-fc fusion protein for use in treating autoimmune diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL304950A (en) * | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CA3032820A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
-
2023
- 2023-02-10 CA CA3243493A patent/CA3243493A1/en active Pending
- 2023-02-10 CN CN202510423645.4A patent/CN120346304A/zh active Pending
- 2023-02-10 JP JP2024547537A patent/JP2025506173A/ja active Pending
- 2023-02-10 CN CN202380019852.2A patent/CN119013034A/zh active Pending
- 2023-02-10 TW TW112104789A patent/TW202400218A/zh unknown
- 2023-02-10 KR KR1020247030225A patent/KR20240148001A/ko active Pending
- 2023-02-10 EP EP23709093.1A patent/EP4475875A1/en active Pending
- 2023-02-10 AU AU2023219773A patent/AU2023219773A1/en active Pending
- 2023-02-10 MX MX2024009868A patent/MX2024009868A/es unknown
- 2023-02-10 US US18/167,529 patent/US20230390360A1/en active Pending
- 2023-02-10 WO PCT/US2023/062395 patent/WO2023154870A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240148001A (ko) | 2024-10-10 |
| TW202400218A (zh) | 2024-01-01 |
| AU2023219773A1 (en) | 2024-08-01 |
| CA3243493A1 (en) | 2023-08-17 |
| JP2025506173A (ja) | 2025-03-07 |
| EP4475875A1 (en) | 2024-12-18 |
| CN119013034A (zh) | 2024-11-22 |
| MX2024009868A (es) | 2024-08-20 |
| WO2023154870A1 (en) | 2023-08-17 |
| US20230390360A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119013034A (zh) | 用于治疗自身免疫性疾病的白细胞介素-2突变蛋白 | |
| US20250059249A1 (en) | Interleukin-2 agents and uses thereof | |
| CN106573966B (zh) | 用于治疗代谢异常的组合物和方法 | |
| DK1868635T3 (en) | METHODS OF TREATING IMMUNE DISEASES IN CONNECTION WITH ORGAN TRANSPLANTATION WITH SOLUBLE, Mutating CTLA4 MOLECULES | |
| US20220226442A1 (en) | Interleukin-2 agents and uses thereof | |
| RS62630B9 (sr) | Modulatori aktivnosti komplementa | |
| JP2023055875A (ja) | Hiv融合体を標的とするポリペプチド | |
| US11603387B2 (en) | SOCS mimetics for the treatment of diseases | |
| AU2013344973B2 (en) | Compositions and methods for the treatment of ectodermal dysplasia | |
| HK40124714A (en) | Interleukin-2 muteins for the treatment of autoimmune diseases | |
| HK40113125A (en) | Interleukin-2 muteins for the treatment of autoimmune diseases | |
| JP2025530309A (ja) | 自閉症スペクトラム障害の処置に使用するためのインターロイキン-2 | |
| CN116635055A (zh) | 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物 | |
| HK40098728A (en) | Interleukin-2 mutants and uses thereof | |
| CN116997351A (zh) | 白介素-2突变体及其用途 | |
| HK40110548A (en) | Methods of using interleukin-2 agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40124714 Country of ref document: HK |